tetano
Editor, Senior Moderator
Chest. 2020 Mar 31. pii: S0012-3692(20)30571-7. doi: 10.1016/j.chest.2020.03.039. [Epub ahead of print]
Treatment with convalescent plasma for critically ill patients with SARS-CoV-2 infection.
Zhang B[SUP]1[/SUP], Liu S[SUP]1[/SUP], Tan T[SUP]2[/SUP], Huang W[SUP]1[/SUP], Dong Y[SUP]3[/SUP], Chen L[SUP]1[/SUP], Chen Q[SUP]1[/SUP], Zhang L[SUP]1[/SUP], Zhong Q[SUP]4[/SUP], Zhang X[SUP]5[/SUP], Zou Y[SUP]6[/SUP], Zhang S[SUP]7[/SUP].
Author information
Abstract
As of March 24, 2020, novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been responsible for 379,661 infection cases with 16,428 deaths globally and the number is still increasing rapidly. Herein, we presented four critically ill patients with SARS-CoV-2 infection who received supportive care and convalescent plasma. Although all the four patients (including a pregnant woman) recovered from SARS-CoV-2 infection eventually, randomized trials are needed to eliminate the effect of other treatments and investigate the safety and efficacy of convalescent plasma therapy.
Copyright ? 2020. Published by Elsevier Inc.
KEYWORDS:
Convalescent plasma; Critically illness; SARS-CoV-2
PMID:32243945DOI:10.1016/j.chest.2020.03.039
Treatment with convalescent plasma for critically ill patients with SARS-CoV-2 infection.
Zhang B[SUP]1[/SUP], Liu S[SUP]1[/SUP], Tan T[SUP]2[/SUP], Huang W[SUP]1[/SUP], Dong Y[SUP]3[/SUP], Chen L[SUP]1[/SUP], Chen Q[SUP]1[/SUP], Zhang L[SUP]1[/SUP], Zhong Q[SUP]4[/SUP], Zhang X[SUP]5[/SUP], Zou Y[SUP]6[/SUP], Zhang S[SUP]7[/SUP].
Author information
Abstract
As of March 24, 2020, novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been responsible for 379,661 infection cases with 16,428 deaths globally and the number is still increasing rapidly. Herein, we presented four critically ill patients with SARS-CoV-2 infection who received supportive care and convalescent plasma. Although all the four patients (including a pregnant woman) recovered from SARS-CoV-2 infection eventually, randomized trials are needed to eliminate the effect of other treatments and investigate the safety and efficacy of convalescent plasma therapy.
Copyright ? 2020. Published by Elsevier Inc.
KEYWORDS:
Convalescent plasma; Critically illness; SARS-CoV-2
PMID:32243945DOI:10.1016/j.chest.2020.03.039